DIGESTIVE NEUROENDOCRINE TUMORS: RECLASSIFYING OF 26 CASES ACCORDING TO 2010 WHO CLASSIFICATION.

##plugins.themes.academic_pro.article.sidebar##

Published May 17, 2017
Download
pdf
Vol. 94 No. 10 (2016): Issue Oct 2016

##plugins.themes.academic_pro.article.main##

Abir Chaabane
Issam M'sakni
Basma Laabidi
Fathi Bougrine
Ammar Bouziani

Abstract

Background: The classification of digestive neuroendocrine tumors is difficult due to their heterogeneity and rareness.
Aims : Reclassify the digestive neuroendocrine tumors according  to  the  WHO-2010 classification .
 Methods: A retrospective study included   26 patients having digestive neuroendocrine     tumors ,  is achieved  in our  Pathology  Laboratory  of the Military Hospital of  Tunis between 2000 and 2013.
Results: The mean age of patients was 49.64 years. The Sex ratio was  1.36. It was 6 gastric tumors, 5 small intestine tumors , 5 pancreatic tumors, 5  appendix tumors , one hypatic tumor, one  gall bladder  tumor , one rectal tumor and one colon tumor. According to the WHO -2000 classification, tumors are categorised into 11 well differentiated  endocrine tumors, 13 well differentiated  endocrine carcinoma  and 2 poorly differentiated carcinoma . According to the WHO -2010 classification, tumors were re-evaluated as  16 neuroendocrine tumors grade 1, 6 neuroendocrine tumors grade 2 and 4 neuroendocrine carcinoma .
Conclusion: There was a concordance between the two classifications in 93% of cases. The WHO -2010 classification may allow a  better classification for the digestive neuroendocrine tumors, however there are some histological categories that remained difficult to classify

 

Keywords:

Tumor, neuroendocrine, classification, Ki-67

##plugins.themes.academic_pro.article.details##

References

  1. Walter T, Scoazec J-Y, Lepage C. Épidémiologie des tumeurs neuroendocrines digestives: la situation en France. Hépato-gastro & oncologie digestive. 2013; 20(3): 160-6.
  2. World Health Organization, International Agency for Research on Cancer. WHO classification of tumours of the digestive system. 4th ed. Lyon: International Agency for Research on Cancer, 2010.
  3. Scarpa A, Mantovani W, Capelli P, et al. Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol. 2010; 23(6): 824-33.
  4. Saint-André J-P. Système des cellules neuroendocrines. Endocrinologie - Nutrition. 2000; 10(1): 1-8.
  5. Klöppel G, Rindi G, Anlauf M, Perren A, Komminoth P. Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors. Virchows Arch. 2007; 451 (Suppl 1): S9-27.
  6. Niederle MB, Niederle B. Diagnosis and treatment of gastroenteropancreatic neuroendocrine tumors: current data on a prospectively collected, retrospectively analyzed clinical multicenter investigation. Oncologist. 2011;16(5): 602-13.
  7. Turaga KK, Kvols LK. Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin. 2011; 61(2): 113-32.
  8. Alsina M, Marcos-Gragera R, Capdevila J, et al. Neuroendocrine tumors: a population-based study of incidence and survival in Girona Province, 1994- 2004. Cancer Epidemiol. 2011; 35(6): 49-54.
  9. Hauso O, Gustafsson BI, Kidd M, et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer. 2008; 113(10): 2655-64.
  10. Auernhammer CJ, Göke B. Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin. Gut. 2011; 60(7): 1009-21.
  11. Frilling A, Akerström G, Falconi M, et al. Neuroendocrine tumor disease: an evolving landscape. Endocr Relat Cancer. 2012; 19(5): 163-85.
  12. Yao JC, Hassan M, Phan A, et al. One hundred years after « carcinoid »: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008; 26(18): 3063-72.
  13. Lepage C, Ciccolallo L, De Angelis R, et al. European disparities in malignant digestive endocrine tumours survival. Int J Cancer. 2010; 126(12): 2928-34.
  14. Ben Ameur H. Les tumeurs endocrines digestives: Résultats d'une étude multicentrique tunisienne. Médecine du Maghreb. 2013; 212: 19-29.
  15. R Rjiba. Les tumeurs endocrines digestives: aspects cliniques et modalités thérapeutiques, à propos de neuf cas. La tunisie Medicale. 2011; 89(01):103.
  16. Calender A. Néoplasie endocrinienne multiple de type 1 : aspects génétiques et cliniques. Gastroentérologie Clinique et Biologique. 2001; 25(4): 38.
  17. Baudin E. Gastroenteropancreatic endocrine tumors: clinical characterization before therapy. Nat Clin Pract Endocrinol Metab. 2007; 3(3): 228-39.
  18. Habal N, Sims C, Bilchik AJ. Gastrointestinal carcinoid tumors and second primary malignancies. J Surg Oncol. 2000; 75(4): 310-6.
  19. Calzada M, Keller I, Potier L, et al. Médecine nucléaire et imagerie multimodalités des tumeurs endocrines. Médecine Nucléaire. 2010; 34(8): 444-50.
  20. Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current status of gastrointestinal carcinoids. Gastroenterology. 2005; 128(6): 1717-51.
  21. Niederle MB, Hackl M, Kaserer K, Niederle B. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocrine RelatedCancer. 2010; 17(4): 909-18.
  22. Pape U-F, Jann H, Müller-Nordhorn J, et al. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer. 2008; 113(2): 256-65.
  23. Klöppel G. Oberndorfer and his successors: from carcinoid to neuroendocrine carcinoma. Endocr Pathol. 2007; 18(3): 141-4.
  24. Capelli P, Fassan M, Scarpa A. Pathology - grading and staging of GEPNETs. Best Pract Res Clin Gastroenterol. 2012; 26(6): 705-17.
  25. Strosberg JR, Nasir A, Hodul P, Kvols L. Biology and Treatment of Metastatic Gastrointestinal Neuroendocrine Tumors. Gastrointest Cancer Res. 2008; 2(3): 113-25.
  26. Ozkara S, Aker F, Yesil A, et al. Re-evaluation of cases with gastroenteropancreatic neuroendocrine tumors between 2004 and 2012 according to the 2010 criteria. Hepatogastroenterology. 2013; 60(127): 1665-72.
  27. Scoazec J-Y. Tumeurs endocrines : biologie et physiopathologie. Annales de pathologie. 2005; 25(6): 447-61.
  28. Tang LH. High grade transformation of differentiated neuroendocrine neoplasms (NENs) of the enteropancreatic system - A unique entity distinct from de novo high grade neuroendocrine carcinoma (HGNECa) in pathogenesis and clinical behavior. Laboratory Investigation. 2008; 88(Suppl.1): 137A.
  29. Vélayoudom-Céphise F-L, Duvillard P, Foucan L, et al. Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endocr Relat Cancer. 2013; 20(5): 649-57.
  30. Yachida S, Vakiani E, White CM, et al. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol. 2012; 36(2): 173-84.
  31. Panzuto F, Nasoni S, Falconi M, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer. 2005; 12(4): 1083-92.
  32. Larghi A, Capurso G, Carnuccio A, et al. Ki-67 grading of nonfunctioning pancreatic neuroendocrine tumors on histologic samples obtained by EUSguided fine-needle tissue acquisition: a prospective study. Gastrointest Endosc. 2012; 76(3): 570-7.
  33. Francesco Panzuto LB. Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011; 29(17): 2372-7.
  34. Bettini R, Boninsegna L, Mantovani W, et al. Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. Ann Oncol. 2008; 19(5):903-8.